Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-01-23 00:00:00 ET · period of report 2026-01-23 · accession 0000907654-26-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-23 | 2026-01-23 | ORKA | Klein Lawrence Otto | CEO, Dir | A - Grant | $0.00 | +76.7K | 929.0K | +9% | $0 |
| D | 2026-01-23 | 2026-01-23 | ORKA | Klein Lawrence Otto | CEO, Dir | A - Grant | $0.00 | +306.7K | 306.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-23 | A | A | 76,700 | $0.00 | 929,038 | D | — | — | (F1) The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). |
| 2 | Derivative | Employee Stock Option (right to buy) | 2026-01-23 | A | A | 306,700 | $0.00 | 306,700 | D | $34.39 · — to 2036-01-22 | 306,700 Common Stock | (F2) The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. |